Table 1.
Description and calibration of CNA variables
| Outcome/Condition | Description | Factor | Calibration |
|---|---|---|---|
| High coverage of community-wide MDA | > 90% (per-protocol) 1 | COVERAGE |
0 < 90% coverage 1 > 90% coverage |
| Drug supply chain | Timing of when albendazole arrive in each cluster | DRUG |
0 Late arrival of albendazole (on first day of MDA) 1 Early arrival of albendazole (at least one day before MDA) |
| Implementer training | Proportion of community drug distributors (CDDs) trained prior to MDA in cluster | TRAIN |
0 Not all CDDs trained 1 All CDDs trained |
| Community sensitization type | Type of community sensitization activity conducted in cluster 2 | MTG, PUBLIC, PRINT, DOOR, RADIO, TV, NEWSPAPER |
0 Sensitization activity not conducted 1 Sensitization activity conducted |
| Intervention duration | Number of days of MDA delivery | MDADAYS4 |
0 MDA delivered in > 10 days 1 MDA delivered in <= 10 days |
| Implementation context | Presence of ongoing interventions or events in the community that may have negatively impacted MDA delivery or uptake | CONTEXT |
0 Non-conducive implementation context (at least one ongoing community intervention or event) 1 Conducive implementation context (no community interventions or events) |
1Per-protocol coverage defined as: the percentage of censused and eligible individuals treated with a single dose of albendazole.
2Sensitization activities incudes: community meetings (MTG), public address announcements (PUBLIC), distribution of printed education materials e.g., posters and banners (PRINT), door-to-door sensitization (DOOR), or mass media (RADIO, TV, NEWSPAPER).
3Television (TV) and news (NEWSPAPER) were removed from final dataset due to limited variation across cases.
4CDDs who participated in DeWorm3 were given 10 days to deliver community-wide MDA.